Regenxbio Inc (RGNX NASDAQ) stock market data APIs
$10.3572
0.37(3.6%)
as of February 6, 2026
Try our APIs with
free plan!
Regenxbio Inc Financial Data Overview
Price chart is built with
Anychart
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Prev. Close
10.3572
Open
10.7239
High
10.8801
Low
10.334
52 wk Range
5.035-16.19
Market Cap
519 M
Shares Outstanding
50 623 K
Revenue
161 M
EPS
-1.2
Beta
1.053
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Regenxbio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Regenxbio Inc data using free add-ons & libraries
Get Regenxbio Inc Fundamental Data
Regenxbio Inc Fundamental data includes:
- Net Revenue: 161 M
- EBITDA: -139 160 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -1.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regenxbio Inc News
New
Regenxbio selloff ‘an overreaction’ to clinical hold, says Leerink
After Regenxbio (RGNX) disclosed the FDA put a clinical hold on RGX-111 for Hurler syndrome and on the RGX-121 study for Hunter syndrome, Leerink said the roughly 30% premarket selloff in shares under...
Biotech Stocks Facing FDA Decision In February 2026
(RTTNews) - As January 2026 comes to a close, it is time to reflect on the regulatory developments of the month and look ahead to what's in store in February. On January 13, 2026, Sentynl Therapeutic...
Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope.
Sarepta Therapeutics stock jumped after the company unveiled positive top-line results for a study measuring the efficacy of Elevidys, its controversial blockbuster treatment for Duchenne muscular dys...
REGENXBIO Inc. (RGNX): A Bull Case Theory
We came across a bullish thesis on REGENXBIO Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on RGNX. REGENXBIO Inc.'s share was trading at $13.76 as of J...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
